NYSE:BSX - Boston Scientific Stock Price, Price Target & More

$28.84 -0.05 (-0.17 %)
(As of 04/22/2018 04:12 AM ET)
Previous Close$28.84
Today's Range$28.82 - $29.15
52-Week Range$24.54 - $29.93
Volume8.66 million shs
Average Volume7.12 million shs
Market Capitalization$39.72 billion
P/E Ratio22.89
Dividend YieldN/A
Beta0.81

About Boston Scientific (NYSE:BSX)

Boston Scientific logoBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.54%
Current Ratio0.68%
Quick Ratio0.49%

Price-To-Earnings

Trailing P/E Ratio22.89
Forward P/E Ratio21.05
P/E Growth2.09

Sales & Book Value

Annual Sales$9.05 billion
Price / Sales4.38
Cash Flow$1.8911 per share
Price / Cash15.25
Book Value$5.11 per share
Price / Book5.64

Profitability

EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins1.15%
Return on Equity24.27%
Return on Assets9.48%

Miscellaneous

Employees29,000
Outstanding Shares1,374,910,000

How to Become a New Pot Stock Millionaire

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific (NYSE:BSX) posted its quarterly earnings data on Thursday, February, 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the Zacks' consensus estimate of $0.34. The medical equipment provider had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The business's revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the business earned $0.30 earnings per share. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $1.35-1.39 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of $9.650-$9.800 billion, compared to the consensus revenue estimate of $9.60 billion.Boston Scientific also updated its Q1 guidance to $0.30-0.32 EPS.

What price target have analysts set for BSX?

19 brokers have issued 12 month target prices for Boston Scientific's shares. Their forecasts range from $27.00 to $35.00. On average, they expect Boston Scientific's share price to reach $31.3684 in the next year. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, based on the recent announcement, we believe further delay in relaunch of the earlier-recalled Lotus range of heart devices is expected to hamper sales in 2018 too. In the past three months, Boston Scientific has been trading below the broader industry." (1/30/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
  • 3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
  • 4. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)

Has Boston Scientific been receiving favorable news coverage?

Media stories about BSX stock have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Boston Scientific earned a news sentiment score of 0.18 on Accern's scale. They also assigned news stories about the medical equipment provider an impact score of 47.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $28.84.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $39.72 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  621 (Vote Outperform)
Underperform Votes:  564 (Vote Underperform)
Total Votes:  1,185
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Boston Scientific (NYSE:BSX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Boston Scientific in the last 12 months. Their average twelve-month price target is $31.3684, suggesting that the stock has a possible upside of 8.77%. The high price target for BSX is $35.00 and the low price target for BSX is $27.00. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.842.842.832.78
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.3684$31.0556$30.8750$30.9667
Price Target Upside: 8.77% upside11.31% upside13.30% upside4.58% upside

Boston Scientific (NYSE:BSX) Consensus Price Target History

Price Target History for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018Bank of AmericaBoost Price TargetBuy -> Buy$30.00 -> $34.00LowView Rating Details
3/27/2018Needham & Company LLCReiterated RatingBuy$35.00HighView Rating Details
3/19/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$30.00 -> $33.00LowView Rating Details
3/5/2018Royal Bank of CanadaReiterated RatingTop Pick$32.00MediumView Rating Details
2/23/2018Piper JaffrayInitiated CoverageOverweight -> Overweight$31.00MediumView Rating Details
2/2/2018Jefferies GroupReiterated RatingHold -> NeutralLowView Rating Details
1/17/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
1/10/2018BarclaysReiterated RatingBuy$32.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageIn -> In-Line$27.00MediumView Rating Details
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00LowView Rating Details
12/4/2017SunTrust BanksSet Price TargetBuy$33.00LowView Rating Details
11/30/2017CowenSet Price TargetBuy$31.00LowView Rating Details
11/30/2017BTIG ResearchUpgradeNeutral -> Buy$31.00MediumView Rating Details
11/29/2017JPMorgan ChaseReiterated RatingBuyLowView Rating Details
11/29/2017OppenheimerReiterated RatingHoldHighView Rating Details
9/25/2017Stifel NicolausReiterated RatingBuy$32.00LowView Rating Details
8/1/2017UBSReiterated RatingBuy$30.00 -> $31.00LowView Rating Details
6/16/2017Wells FargoReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman SachsInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
10/6/2016CitigroupBoost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016BenchmarkBoost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Boston Scientific (NYSE:BSX) Earnings History and Estimates Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Earnings Estimates

2018 EPS Consensus Estimate: $1.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.31$0.32$0.31
Q2 20184$0.35$0.35$0.35
Q3 20185$0.33$0.36$0.34
Q4 20184$0.36$0.37$0.37

Boston Scientific (NYSE BSX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.32N/AView Earnings Details
2/1/2018Q4 2017$0.34$0.34$2.3925 billion$2.4080 billionViewListenView Earnings Details
10/26/2017Q3 2017$0.31$0.31$2.2127 billion$2.2220 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.2122 billion$2.2570 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.0819 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.8287 billion$1.8380 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.7881 billion$1.7610 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
10/19/2010Q3 2010$0.06$0.12ViewN/AView Earnings Details
7/20/2010Q2 2010$0.03$0.06ViewN/AView Earnings Details
4/26/2010Q1 2010$0.08$0.09ViewN/AView Earnings Details
2/10/2010Q4 2009$0.13$0.20ViewN/AView Earnings Details
10/19/2009Q3 2009$0.14$0.12ViewN/AView Earnings Details
7/20/2009Q2 2009$0.13$0.20ViewN/AView Earnings Details
4/20/2009Q1 2009$0.12$0.13ViewN/AView Earnings Details
1/28/2009Q4 2008$0.13$0.12ViewN/AView Earnings Details
10/21/2008Q3 2008$0.11$0.16ViewN/AView Earnings Details
7/21/2008Q2 2008$0.11$0.13ViewN/AView Earnings Details
4/21/2008Q1 2008$0.12$0.17ViewN/AView Earnings Details
2/4/2008Q4 2007$0.10$0.24ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Boston Scientific (NYSE:BSX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 91.05%
Insider Trading History for Boston Scientific (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018David A PierceEVPSell5,000$27.22$136,100.00View SEC Filing  
3/20/2018John Bradley SorensonSVPSell2,200$27.63$60,786.0034,636View SEC Filing  
3/19/2018Daniel J BrennanCFOSell60,209$27.87$1,678,024.83299,644View SEC Filing  
3/14/2018Kevin J BallingerEVPSell42,803$28.32$1,212,180.96View SEC Filing  
3/5/2018John Bradley SorensonSVPSell1,950$27.43$53,488.50View SEC Filing  
2/28/2018David A PierceSVPSell4,508$27.54$124,150.32View SEC Filing  
2/21/2018David A PierceSVPSell16,286$27.00$439,722.00View SEC Filing  
2/9/2018Maulik NanavatySVPSell15,568$25.38$395,115.84View SEC Filing  
2/7/2018Joseph Michael FitzgeraldEVPSell85,227$26.48$2,256,810.96View SEC Filing  
2/1/2018David A PierceSVPSell5,152$27.43$141,319.3629,353View SEC Filing  
1/11/2018David A PierceSVPSell8,763$27.74$243,085.6224,201View SEC Filing  
1/9/2018David A PierceSVPSell5,152$27.00$139,104.0038,116View SEC Filing  
12/29/2017Michael P PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/29/2017Michael P. PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/1/2017Timothy A PrattEVPSell10,000$26.04$260,400.00154,681View SEC Filing  
12/1/2017Valley Gold Master Fund L SunInsiderBuy27,431$0.44$12,069.64
11/29/2017Michael P. PhalenEVPSell15,500$26.66$413,230.00View SEC Filing  
11/28/2017Valley Gold Master Fund L SunInsiderBuy408,006$0.45$183,602.70
11/1/2017Timothy A PrattEVPSell10,000$28.22$282,200.00164,681View SEC Filing  
10/30/2017Michael P. PhalenEVPSell15,500$28.42$440,510.00View SEC Filing  
10/4/2017Supratim BoseEVPSell347,137$29.12$10,108,629.44View SEC Filing  
10/2/2017Timothy A PrattEVPSell11,061$29.24$323,423.64174,681View SEC Filing  
9/29/2017Michael P. PhalenEVPSell15,500$28.72$445,160.00View SEC Filing  
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84185,742View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.0021,680View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00195,846View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.0018,880View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84235,421View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00205,846View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.0033,701View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.4028,572View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00215,846View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00225,846View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.0035,850View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.0020,980View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00235,846View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.1225,600View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40245,846View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.2834,267View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88248,758View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.4375,864View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.6825,600View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80231,273View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48260,430View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.0012,615View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.001,388,177View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00287,495View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.4028,080View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.001,532,577View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14301,724View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.0015,115View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00150,227View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.4671,975View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.6092,020View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.001,632,577View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00308,724View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.3483,600View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80291,724View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.0096,634View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.001,732,577View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00355,651View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.0046,970View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.6938,395View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.0589,309View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.001,832,577View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96338,651View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42202,659View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.0041,598View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.8023,647View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20303,776View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.0730,323View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.0082,535View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00282,295View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.0086,032View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.925,605View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60103,925View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00289,295View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.0081,262View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00315,893View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00319,393View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00322,893View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.0092,983View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.0092,983View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00127,486View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00317,855View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00127,486View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00327,855View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00127,486View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.0443,161View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64127,486View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.5347,990View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14130,848View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.7825,600View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.8484,300View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.0087,522View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.003,124View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20347,855View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00364,959View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00374,959View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00384,959View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92109,042View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.0039,190View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00147,447View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.0493,191View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.8873,519View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Boston Scientific (NYSE BSX) News Headlines

Source:
DateHeadline
Boston Scientific (BSX) Expected to Post Quarterly Sales of $2.34 BillionBoston Scientific (BSX) Expected to Post Quarterly Sales of $2.34 Billion
www.americanbankingnews.com - April 21 at 2:32 AM
Boston Scientific (BSX) Earns Buy Rating from BMO Capital MarketsBoston Scientific (BSX) Earns Buy Rating from BMO Capital Markets
www.americanbankingnews.com - April 20 at 6:54 PM
$0.31 EPS Expected for Boston Scientific (BSX) This Quarter$0.31 EPS Expected for Boston Scientific (BSX) This Quarter
www.americanbankingnews.com - April 19 at 7:21 PM
Boston Scientific (BSX) Downgraded by Zacks Investment Research to "Sell"Boston Scientific (BSX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 19 at 11:46 AM
Boston Scientific (BSX) Given "Buy" Rating at Royal Bank of CanadaBoston Scientific (BSX) Given "Buy" Rating at Royal Bank of Canada
www.americanbankingnews.com - April 19 at 12:28 AM
Boston Scientific buys Harker School grads med-tech business for $275MBoston Scientific buys Harker School grad's med-tech business for $275M
www.bizjournals.com - April 18 at 10:39 AM
Boston Scientific (BSX) Scheduled to Post Quarterly Earnings on WednesdayBoston Scientific (BSX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 2:46 AM
Boston Scientific (BSX) Receives Outperform Rating from CowenBoston Scientific (BSX) Receives Outperform Rating from Cowen
www.americanbankingnews.com - April 17 at 11:28 PM
Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?
www.zacks.com - April 17 at 10:45 AM
Boston Scientific Prevails In European Patent Dispute With Edwards LifesciencesBoston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
finance.yahoo.com - April 17 at 10:45 AM
Boston Scientific buys nVision Medical for $275 millionBoston Scientific buys nVision Medical for $275 million
finance.yahoo.com - April 17 at 10:45 AM
How Profiteers Lure Women Into Often-Unneeded SurgeryHow Profiteers Lure Women Into Often-Unneeded Surgery
www.nytimes.com - April 16 at 3:43 PM
BRIEF-Boston Scientific Announces Acquisition Of NVision Medical CorpBRIEF-Boston Scientific Announces Acquisition Of NVision Medical Corp
www.reuters.com - April 16 at 3:43 PM
Boston Scientific (BSX) Downgraded by BidaskClub to "Hold"Boston Scientific (BSX) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 16 at 11:39 AM
Boston Scientific acquires nVision Medical for up to $275MBoston Scientific acquires nVision Medical for up to $275M
seekingalpha.com - April 16 at 10:27 AM
Boston Scientific Acquires NVision Medical In Up To $275 Mln Deal - Quick FactsBoston Scientific Acquires NVision Medical In Up To $275 Mln Deal - Quick Facts
www.nasdaq.com - April 16 at 10:27 AM
Boston Scientific Announces Acquisition Of nVision Medical CorporationBoston Scientific Announces Acquisition Of nVision Medical Corporation
finance.yahoo.com - April 16 at 10:27 AM
A 32-Year-Olds Startup, Inspired By A Health Scare, Sells For $275 MillionA 32-Year-Old's Startup, Inspired By A Health Scare, Sells For $275 Million
finance.yahoo.com - April 16 at 10:27 AM
Boston Scientific (BSX) Rating Reiterated by CowenBoston Scientific (BSX) Rating Reiterated by Cowen
www.americanbankingnews.com - April 15 at 9:31 AM
Boston Scientific (BSX) Upgraded by Zacks Investment Research to "Hold"Boston Scientific (BSX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 15 at 8:37 AM
Boston Scientific (BSX) Cut to "Sell" at BidaskClubBoston Scientific (BSX) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM
WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid WoesWATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes
finance.yahoo.com - April 12 at 11:34 AM
MitraClip Drives Growth, Gets Reimbursement Approval in JapanMitraClip Drives Growth, Gets Reimbursement Approval in Japan
finance.yahoo.com - April 9 at 3:37 PM
SunTrust Banks Reaffirms "Buy" Rating for Boston Scientific (BSX)SunTrust Banks Reaffirms "Buy" Rating for Boston Scientific (BSX)
www.americanbankingnews.com - April 8 at 4:51 PM
Needham & Company LLC Reiterates Buy Rating for Boston Scientific (BSX)Needham & Company LLC Reiterates Buy Rating for Boston Scientific (BSX)
www.americanbankingnews.com - April 8 at 11:05 AM
Boston Scientific (BSX) PT Raised to $34 at BofA/Merrill LynchBoston Scientific (BSX) PT Raised to $34 at BofA/Merrill Lynch
www.streetinsider.com - April 7 at 1:56 PM
Boston Scientific (BSX) Earns Buy Rating from Analysts at Canaccord GenuityBoston Scientific (BSX) Earns Buy Rating from Analysts at Canaccord Genuity
www.americanbankingnews.com - April 5 at 9:36 PM
Boston Scientific (BSX) Price Target Increased to $34.00 by Analysts at Bank of AmericaBoston Scientific (BSX) Price Target Increased to $34.00 by Analysts at Bank of America
www.americanbankingnews.com - April 5 at 1:11 PM
What’s behind Edwards Lifesciences’ Stock Rise?What’s behind Edwards Lifesciences’ Stock Rise?
finance.yahoo.com - April 4 at 2:28 PM
Boston Scientific to Acquire Securus Medical, Boost EP UnitBoston Scientific to Acquire Securus Medical, Boost EP Unit
finance.yahoo.com - April 4 at 2:28 PM
Edwards Lifesciences and Boston Scientific: Patent Dispute UpdateEdwards Lifesciences and Boston Scientific: Patent Dispute Update
finance.yahoo.com - April 4 at 2:28 PM
Boston Scientific Announces Acquisition of Securus MedicalBoston Scientific Announces Acquisition of Securus Medical
finance.yahoo.com - April 4 at 2:28 PM
Wall Street’s Recommendations for BSX StockWall Street’s Recommendations for BSX Stock
finance.yahoo.com - April 4 at 2:28 PM
Boston Scientific (BSX) Downgraded by Zacks Investment Research to "Hold"Boston Scientific (BSX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 4 at 1:21 PM
Boston Scientific Co. (BSX) Receives Average Rating of "Buy" from AnalystsBoston Scientific Co. (BSX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 11:51 AM
Zacks: Brokerages Anticipate Boston Scientific Co. (BSX) Will Announce Quarterly Sales of $2.34 BillionZacks: Brokerages Anticipate Boston Scientific Co. (BSX) Will Announce Quarterly Sales of $2.34 Billion
www.americanbankingnews.com - April 4 at 2:14 AM
David A. Pierce Sells 5,000 Shares of Boston Scientific Co. (BSX) StockDavid A. Pierce Sells 5,000 Shares of Boston Scientific Co. (BSX) Stock
www.americanbankingnews.com - April 3 at 10:31 PM
Boston Scientific (BSX) Rating Lowered to Hold at ValuEngineBoston Scientific (BSX) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 6:26 PM
Boston Scientific (BSX) Buys Securus Medical Group for $40 Million Up-Front and $10 Million ContingentBoston Scientific (BSX) Buys Securus Medical Group for $40 Million Up-Front and $10 Million Contingent
www.streetinsider.com - April 3 at 10:57 AM
 Brokerages Expect Boston Scientific Co. (BSX) to Post $0.31 EPS Brokerages Expect Boston Scientific Co. (BSX) to Post $0.31 EPS
www.americanbankingnews.com - April 2 at 7:10 PM
Boston Scientific (BSX) Given Buy Rating at Royal Bank of CanadaBoston Scientific (BSX) Given Buy Rating at Royal Bank of Canada
www.americanbankingnews.com - April 1 at 6:28 PM
Boston Scientific (BSX) Coverage Initiated by Analysts at Evercore ISIBoston Scientific (BSX) Coverage Initiated by Analysts at Evercore ISI
www.americanbankingnews.com - March 30 at 11:40 PM
More Controversy Over Major Cardiology Clinical TrialMore Controversy Over Major Cardiology Clinical Trial
finance.yahoo.com - March 30 at 3:34 PM
Boston Scientific (BSX) Stock Rating Lowered by Zacks Investment ResearchBoston Scientific (BSX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:36 PM
These medical devices are getting better at treating chronic painThese medical devices are getting better at treating chronic pain
finance.yahoo.com - March 29 at 11:04 AM
Baxter International Created a New Reporting Structure for 2018Baxter International Created a New Reporting Structure for 2018
finance.yahoo.com - March 28 at 3:33 PM
Boston Scientifics (BSX) "Buy" Rating Reiterated at Needham & Company LLCBoston Scientific's (BSX) "Buy" Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - March 28 at 12:58 PM
How Do Analysts See Boston Scientific Corporation (NYSE:BSX) Performing Over The Next Few Years?How Do Analysts See Boston Scientific Corporation (NYSE:BSX) Performing Over The Next Few Years?
finance.yahoo.com - March 28 at 10:39 AM
Boston Scientific Prevails In U.K. Edwards Lifesciences LitigationBoston Scientific Prevails In U.K. Edwards Lifesciences Litigation
www.prnewswire.com - March 28 at 5:58 AM
Boston Scientific cuts nearly 300 workers at Los Angeles facilityBoston Scientific cuts nearly 300 workers at Los Angeles facility
www.bizjournals.com - March 27 at 3:43 PM

SEC Filings

Boston Scientific (NYSE:BSX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Boston Scientific (NYSE BSX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.